About - ABBVIE

The pursuit of scientific breakthroughs is more important than ever. It takes unwavering commitment and confidence to bring solutions from the petri dish to patients. And it requires a continued investment in innovation to address the known and unknown challenges of tomorrow. Since our launch in 2013, we have invested ~$50 billion in research to discover, develop and deliver new medicines. We target diseases with significant unmet need where we can improve the standard of care with innovative new therapies. We?re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients? lives, on societies?and on science itself. Today, our ~50,000 employees around the world focus on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women?s health, as well as through our Allergan Aesthetics portfolio. We care deeply for patients and customers, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. We embrace diverse backgrounds and perspectives and treat everyone equally, with dignity and respect, allowing us all to achieve our best. Our commitment to health doesn?t stop with our medicines. Each day, we work to deliver sustainable solutions that improve the health of our business and the health of humankind.

Facts about ABBVIE

CEO Stock Price Founder Headquarters Revenue Founded Area Served
Richard A. Gonzalez 136.28 USD S Nikhil Kumar - Founder North Chicago, Illinois, United States 5,620 crores USD Worldwide

Company Information

Employees: 50,000
Branch: 170
Products: Pharmaceutical drugs & vaccines

ABBVIE - Press Releases

Presrelease Not Found..!